Google Life Sciences has partnered with the American Heart Association (AHA) in efforts to research coronary heart disease also known as atherosclerosis. The $50 million dollars collaboration, will unroll within the next five years according to the Wall Street Journal. Coronary artery disease (the cause of coronary heart disease) starts developing in childhood, therefore it's considered one of the most destructive diseases taking away 7 million lives each year. In the interview to the Huffington Post, Dr. Andrew Conrad, the CEO of Google Life Sciences division shared that both parties are open to bring on board new fresh ideas and people behind them.
Sometimes even a color can become the point point in a law suit. An India-based pharmaceuticals manufacturer company Dr. Reddy's was stopped from selling a generic version of Nexium (AstraZeneca) in the US by the federal district court in Delaware. AstraZeneca argued that the color of the generic Dr. Reddy's drug is violating the trademarked purple color of Nexium. Its stated that over the years AstraZeneca spent billions of dollars branding Nexium as "the purple pill" and having its analog in purple circulating around would be misleading Nexium consumers. AstraZeneca's Nexium, who has been previously named as one of the Pharma's Biggest Drug Blockbusters by Forbes and Medscape, has made 3.655 billion of dollars in revenue in 2014.
Under the guidance of mHealth researcher and activist from University of Michigan a group of students have created a smart phone health app called Diabeticons that helps children to visual communicate about diabetes. Just like any other emoticon app, Diabeticons customizes the mood and provides an easy way to describe how the person with diabetes feels at any given moment. Reportedly the app includes such emoticons as banana and a cupcake that both indicate low blood sugar.
Stay tuned for our weekly news round up!
Subscribe to our Blog or follow us on Twitter: @epharma